HOME >> BIOLOGY >> NEWS
OHSU team discovers compound that lacks estrogen's risks

and Rnnekleiv.

STX appears to act by stimulating a novel estrogen receptor, located in the cell membrane, that activates proteins involved in rapid cell signaling. In this way, it avoids the uterus and breasts, whose growth is stimulated by estrogen through a different pathway, leading to increased cancer risk.

The hypothalamus "controls all autonomic functions and maintains homeostasis eating, drinking, sex behavior, maternal and even paternal behavior," Kelly said. In particular, hypothalamic POMC neurons, which are especially sensitive to STX, "are what activate the natural reward pathways. This is the brain's endogenous opiate system."

Having a selective estrogen trigger for rapid signaling is critical for estrogen replacement therapy, Kelly said. STX is structurally distinct from tamoxifen and raloxifene, and it's about 10 times more potent than estrogen and has the potential to be more effective at maintaining cognitive performance of postmenopausal women.

"Women that don't have hormone replacement therapy have been known to have more cognitive impairment in terms of loss of memory, and a higher incidence of Alzheimer's disease," Kelly said. "At least at the basic level, existing SERMs do not seem to help. So the search was on for other compounds one can use to replace tamoxifen. The collaboration with Dr. Scanlan at UCSF made it possible to synthesize and test a series of related compounds before we came up with STX."

Despite the discovery of STX, Rnnekleiv stopped short of rejecting estrogen as an effective therapy, saying its many benefits far outweigh the risks that studies have yet to unequivocally demonstrate.

"Estrogen definitely has neuroprotective effects in the brain," Rnnekleiv said. "At least in animal models, it's been shown that estrogen can reduce neuronal cell death from stroke. One of the other important actions of estrogen is to prevent osteoporosis."

Kelly's and Rnnekle
'"/>

Contact: Jonathan Modie
modiej@ohsu.edu
503-494-8231
Oregon Health & Science University
30-Dec-2003


Page: 1 2 3

Related biology news :

1. LSU researcher discovers new bird
2. MIT team discovers memory mechanism
3. SMCM professor discovers cattle hormones that leak into streams and alter fish reproduction
4. UBC researcher discovers control room that regulates immune responses
5. UC Santa Barbara discovers cell survival gene may lead to treatments for degenerative diseases
6. Brain patterns the same whether doing or just watching, Queens researcher discovers
7. Study discovers key to baby-like skin
8. Rutgers researcher discovers melanoma causing gene
9. UI study discovers cells segregate molecules to control signaling
10. Polluted beach closures influenced by full moons and sunlight, surfer-engineer discovers
11. University of Pittsburgh Cancer Institute discovers proteins linked to colon cancer

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: OHSU team discovers compound that lacks estrogen risks

(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/11/2015)... -- Curemark LLC, a privately held drug research and ... III double blind, randomized, placebo-controlled clinical trial to examine ... children ages 3-8 with Autism. Previously, Curemark announced the ... clinical trial for CM-AT in children ages 3-8 with ... chymotrypsin. This new trial will help determine whether all ...
Breaking Biology News(10 mins):Global Genetic Testing Market Outlook 2018 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Curemark, LLC, Launches New Phase III Trial in Expanded Population of Children with Autism 2
(Date:5/27/2015)... , May 26, 2015 Research ... of the "Global Breast Cancer Monoclonal Antibodies ... Globally, Roche seems to dominate the ... inventory. Its block buster molecule, Herceptin has been ... It was found that breast cancer cells become ...
(Date:5/27/2015)... Fla. (PRWEB) May 27, 2015 Expanding ... dental cement manufacturer Avalon Biomed Inc. recently ... of Mokuda Dental Co. Ltd. , the largest ... inroad into the international market for Avalon Biomed, which ... Plus®, award-winning tricalcium silicate-based dental cements that have won ...
(Date:5/27/2015)... Israel , May 27, 2015  Tikcro Technologies ... quarter ended March 31, 2015. ... quarter, we continued pre-clinical work to generate functional specific ... an early stage, we are encouraged by the development ... field as new antibodies which modulate immune checkpoints gain ...
(Date:5/27/2015)... MB (PRWEB) May 27, 2015 ... data to combat disease, Cubresa Inc. today announced ... “Our MR Compatible in-bore PET Scanner uses silicon ... into single-purpose preclinical MRI machines from manufacturers like ... Cubresa, headquartered in Winnipeg, Canada. “This enables simultaneous ...
Breaking Biology Technology:Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 2Global Breast Cancer Monoclonal Antibodies Market Outlook 2020 3Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 2Dental Manufacturer Avalon Biomed Inks Major Deal with Japanese Distributor 3Tikcro Technologies Reports First Quarter 2015 Results 2Tikcro Technologies Reports First Quarter 2015 Results 3Cubresa Launches Simultaneous PET/MRI Technology 2
Cached News: